Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
General Outlook
In simple terms, Akili, Inc. has 78.31 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.335% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -72.086%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -64.784%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -0.723% return, is a testament to Akili, Inc.'s adeptness in optimizing resource deployment. Akili, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.759%. Furthermore, the proficiency of Akili, Inc. in capital utilization is underscored by a remarkable -0.936% return on capital employed.
Stock Prices
Akili, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.5, while its low point bottomed out at $0.46. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Akili, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”